Financings Roundup
Is Tau How? GMS Bets $31.5M on Alzheimer's Phase III Effort
After years of throwing themselves futilely against the beta amyloid wall, companies trying for Alzheimer's disease (AD) therapies are turning away, hoping to find a door that opens on a way to modify the devastating condition.